Short answers, pulled from the story.
Edward Robinson Squibb opened a small laboratory in Brooklyn, New York, in 1858. He began selling pure medical supplies to doctors who demanded higher standards than the industry offered at that time.
Hamilton College graduates William McLaren Bristol and John Ripley Myers purchased the Clinton Pharmaceutical company in 1887. They renamed the business Bristol, Myers and Company in May 1898 after Myers died the following year.
Bristol-Myers and Squibb officially merged in 1989 to form Bristol-Myers Squibb. This consolidation created one of the largest pharmaceutical entities in the United States.
Federal Judge Frederick B. Lacey urged CEO Peter Dolan to step down following the investigation into Plavix distribution collusion. Dolan announced his resignation later that same day in July 2006.
August 2019 saw the acquisition of Celgene for $74 billion or $95 billion including debt. Seventy-five percent of shareholders voted to approve the merger despite opposition from Wellington Management Company and Starboard Value.
In 2024, Apixaban generated 28% of total revenues while nivolumab contributed 19%. Lenalidomide accounted for 12% of revenue, followed by abatacept at 8%.